Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 1/2019

01-01-2019 | Review Article

Role of comorbidities in spondyloarthritis including psoriatic arthritis

Authors: Silvia Scriffignano, Fabio Massimo Perrotta, Antonia De Socio, Ennio Lubrano

Published in: Clinical Rheumatology | Issue 1/2019

Login to get access

Abstract

Spondyloartrhitis (SpA) are a group of diseases characterized by inflammation at articular and entheseal sites. Moreover, patients with SpA suffer from impaired articular function and reduced quality of life. Beyond the articular involvement, SpA and in particular psoriatic arthritis (PsA) are associated with extra-articular manifestations and comorbidities that might increase the burden of the disease. The aim of this article was to review the available evidences on the presence of comorbidities in SpA, including PsA, focusing the attention on the cardiovascular, metabolic aspects, as well as other comorbidities, and their possible management in an integrated manner. Comorbidities in SpA should be carefully evaluated because of their important impact.
Literature
1.
2.
Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J et al (2009) The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783CrossRefPubMed
3.
Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT et al (2011) The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31CrossRefPubMed
4.
5.
De Socio A, Perrotta FM, Grasso GM, Lubrano E (2018) Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of Central Italy: results of the CAMPO-RHE study. Postgrad Med 130:137–141CrossRefPubMed
6.
Lubrano E, Perrotta FM (2017) The role of IL-17 in the treatment of psoriatic arthritis. Expert Rev Clin Immunol 13:815–821CrossRefPubMed
7.
8.
Lubrano E, Cantini F, Mathieu A, Olivieri I, Salvarani C, Scarpa R, Marchesoni A (2017) A national survey on the management of psoriatic arthritis using the Delphi method. Clin Exp Rheumatol 35:214–220PubMed
9.
Marchesoni A, Olivieri I, Salvarani C, Pipitone N, D’Angelo S, Mathieu A et al (2017) Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exp Rheumatol 35:991–1010PubMed
10.
Perrotta FM, Marchesoni A, Lubrano E (2016) Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 43:350–355CrossRefPubMed
11.
Lubrano E, Perrotta FM, Marchesoni A, D’Angelo S, Ramonda R, Addimanda O et al (2015) Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol 42:258–263CrossRefPubMed
12.
Papagoras C, Voulgari PV, Drosos AA (2013) Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 31:612–620PubMed
13.
Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44:1298–1301CrossRefPubMed
14.
Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70:1921–1925CrossRefPubMed
15.
Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M (2008) Trend towards increased arterial stiffness or intima- media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 47:1203–1207CrossRef
16.
Perrotta FM, Scarno A, Carboni A, Bernardo V, Montepaone M, Lubrano E, Spadaro A (2013) Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices. Reumatismo 65:105–112CrossRefPubMed
17.
Kang JH, Chen YH, Lin HC (2010) Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 69:1165–1168CrossRefPubMed
18.
Ahmed N, Prior JA, Chen Y, Hayward R, Mallen CD, Hider SL (2016) Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clin Rheumatol 35:3069–3073CrossRefPubMed
19.
Chen HH, Yeh SY, Chen HY, Lin CL, Sung FC, Kao CH (2014) Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population. Rheumatol Int 34:265–270CrossRefPubMed
20.
Mathieu S, Gossec L, Dougados M, Soubrier M (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63:557–563CrossRef
21.
Ingegnoli F, Gualtierotti R, Artusi C, Lubrano E (2014) Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk. Expert Rev Clin Immunol 10:307–315CrossRefPubMed
22.
van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE (2012) High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol 31:1529–1535CrossRefPubMedPubMedCentral
23.
van der Weijden MA, van der Horst-Bruinsma IE, van Denderen JC, Dijkmans BA, Heymans MW, Lems WF (2012) High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int 23:1683–1690CrossRefPubMed
24.
25.
Pray C, Feroz NI, Haroon N (2017) Bone mineral density and fracture risk in ankylosing spondylitis: a meta-analysis. Calcif Tissue Int 101:182–192CrossRefPubMed
26.
Mease PJ (2017) Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol 29:304–310CrossRefPubMed
27.
Moltó A, Etcheto A, Gossec L, Boudersa N, Claudepierre P, Roux N, Lemeunier L, Martin A, Sparsa L, Coquerelle P, Soubrier M, Perrot S, Dougados M (2018) Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers’ effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis 77:533–540CrossRefPubMed
28.
Fan A, Pereira B, Tournadre A, Tatar Z, Malochet-Guinamand S, Mathieu S, Couderc M, Soubrier M, Dubost JJ (2017) Frequency of concomitant fibromyalgia in rheumatic diseases: monocentric study of 691 patients. Semin Arthritis Rheum 47:129–132CrossRefPubMed
29.
30.
Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27:24–31CrossRef
31.
Chan CYY, Tsang HHL, Lau CS, Chung HY (2017) Prevalence of depressive and anxiety disorders and validation of the hospital anxiety and depression scale as a screening tool in axial spondyloarthritis patients. Int J Rheum Dis 20:317–325CrossRefPubMed
32.
Meesters JJ, Bremander A, Bergman S, Petersson IF, Turkiewicz A, Englund M (2014) The risk for depression in patients with ankylosing spondylitis: a population-based cohort study. Arthritis Res Ther 16:418CrossRefPubMedPubMedCentral
33.
Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, Calguneri M, Kalyoncu U (2012) Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int 32:323–330CrossRefPubMed
34.
Cutolo M, Paolino S, Pizzorni C (2014) Possible contribution of chronic inflammation in the induction of cancer in rheumatic diseases. Clin Exp Rheumatol 32:839–847PubMed
35.
36.
37.
Bonovas S, Minozzi S, Lytras T, González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, Goletti D, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F (2016) Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 15:35–54CrossRefPubMed
38.
van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF et al (2016) Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 75:83–98CrossRefPubMed
39.
Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41:1103–1110CrossRefPubMed
40.
Radner H, Lesperance T, Accortt NA, Solomon DH (2017) Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res (Hoboken) 69:1510–1518CrossRef
41.
42.
43.
Chehimi M, Vidal H, Eljaafari A (2017) Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. J Clin Med 6:68CrossRefPubMedCentral
44.
45.
Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63:195–202CrossRef
46.
Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their cor- relation with disease activity. Ann Rheum Dis 72:1956–1961CrossRefPubMed
47.
Haroon M, Rafiq Chaudhry AB, Fitzgerald O (2016) Higher prevalence of metabolic syndrome in patients with psoriatic arthritis: a comparison with a control group of noninflammatory rheumatologic conditions. J Rheumatol 43:463–464CrossRefPubMed
48.
Eder L, Chandran V, Cook R, Gladman DD (2017) The risk of developing diabetes mellitus in patients with psoriatic arthritis: a cohort study. J Rheumatol 44:286–291CrossRefPubMed
49.
Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ (2014) Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20:500–512CrossRefPubMed
50.
Busquets N, Vaquero CG, Moreno JR, Vilaseca DR, Narváez J, Carmona L, Nolla JM (2014) Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. Reumatol Clin 10:89–93CrossRefPubMed
51.
Gulati AM, Hoff M, Salvesen Ø, Dhainaut A, Semb AG, Kavanaugh A, Haugeberg G (2017) Bone mineral density in patients with psoriatic arthritis: data from the Nord-Trøndelag health study 3. RMD Open 3:e000413CrossRefPubMedPubMedCentral
52.
Marchesoni A, Atzeni F, Spadaro A, Lubrano E, Provenzano G, Cauli A et al (2012) Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 39:849–855CrossRefPubMed
53.
Fan A, Pereira B, Tournadre A, Tatar Z, Malochet-Guinamand S, Mathieu S, Couderc M, Soubrier M, Dubost JJ (2017) Frequency of concomitant fibromyalgia in rheumatic diseases: monocentric study of 691 patients. Semin Arthritis Rheum 47:129–132CrossRefPubMed
54.
Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H et al (2018) The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford) 57:32–40CrossRef
55.
Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O (2016) The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 43:1749–1754CrossRefPubMed
56.
McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, Gladman DD (2014) Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 41:887–896CrossRefPubMed
57.
Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47:351–360CrossRefPubMed
58.
Koo J, Marangell LB, Nakamura M, Armstrong A, Jeon C, Bhutani T, Wu JJ (2017) Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol 31:1999–2009CrossRefPubMed
59.
Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB (2006) The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126:2194–2201CrossRefPubMed
60.
Frentz G, Olsen JH (1999) Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 140:237–242CrossRefPubMed
61.
Wilton KM, Crowson CS, Matteson EL (2016) Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study. Clin Rheumatol 35:2603–2607CrossRefPubMedPubMedCentral
62.
Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G (2015) Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 14:706–714PubMed
63.
Lubrano E, Perrotta FM (2017) Psoriatic arthritis: is it time to treat-to-target or target to treat? Clin Rheumatol 36:2633–2635CrossRefPubMed
Metadata
Title
Role of comorbidities in spondyloarthritis including psoriatic arthritis
Authors
Silvia Scriffignano
Fabio Massimo Perrotta
Antonia De Socio
Ennio Lubrano
Publication date
01-01-2019
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 1/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4332-7

Other articles of this Issue 1/2019

Clinical Rheumatology 1/2019 Go to the issue

Original Article

Taxol alleviates collagen-induced arthritis in mice by inhibiting the formation of microvessels

Case Based Review

Inflammatory arthritis: a unique presentation of human anaplasmosis

Brief Report

Hypertrophic osteoarthropathy: estrogens, prostaglandinE2, prostaglandin A2, and the inflammatory reflex

Letter to the Editor

Infection mitigation a necessity in lupus patients

Original Article

Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis

Review Article

Treatment options for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome in children and adults: a narrative review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits